CISEN(SH:603367) Sou Hu Cai Jing·2025-08-04 07:45Group 1 - The core viewpoint of the news is that Chenxin Pharmaceutical (603367) has experienced a stock price increase of 6.59% as of August 4, 2025, closing at 32.18 yuan, with a trading volume of 490,700 hands and a transaction amount of 1.511 billion yuan [1] - The company reported a total operating revenue of 920 million yuan for Q1 2025, a year-on-year decrease of 19.91%, and a net profit attributable to shareholders of 144 million yuan, down 11.86% year-on-year [1] - The company's liquidity ratios are strong, with a current ratio of 3.540 and a quick ratio of 2.983, while the debt-to-asset ratio stands at 19.23% [1] Group 2 - Chenxin Pharmaceutical has made investments in 18 companies and has participated in 5,000 bidding projects, indicating active engagement in the market [2] - The company holds 230 trademark registrations and 290 patents, showcasing its commitment to intellectual property [2] - Additionally, the company possesses 610 administrative licenses, reflecting its regulatory compliance and operational capabilities [2]